Sfoglia per Autore
The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse
1996-01-01 Nicoletti, F; Zaccone, P; DI MARCO, Roberto; DI MAURO, M; Magro, G; Grasso, S; Mughini, L; Meroni, P; Garotta, G.
Nitric oxide production is not involved in the effects of interleukin-1 beta on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells (vol 19, pg 239, 1994)
1996-01-01 Rasmussen, A. K.; Dimarco, R.; Diamant, M.; Feldtrasmussen, U.; Bendtzen, K.
Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate
1997-01-01 Nicoletti, F; Beltrami, B; Raschi, E; DI MARCO, Roberto; Magro, G; Grasso, S; Bendtzen, K; Fiorelli, G; Meroni, P. L.
Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13
1997-01-01 Nicoletti, F; Mancuso, G; Cusumano, V; DI MARCO, Roberto; Zaccone, P; Bendtzen, K; Teti, G.
Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody
1997-01-01 Nicoletti, F; Zaccone, P; DI MARCO, Roberto; Lunetta, M; Magro, G; Grasso, S; Meroni, P; Garotta, G.
Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats
1998-01-01 Nicoletti, F; Zaccone, P; DI MARCO, Roberto; Magro, G; Grasso, S; Stivala, F; Calori, G; Mughini, L; Meroni, Pl; Garotta, G.
Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-alpha
1998-01-01 DI MARCO, Roberto; Zaccone, P; Condorelli, L; Leonardi, C; Caccamo, F; DI MAURO, C; Meroni, P; Nicoletti, F.
Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b)
1998-01-01 Nicoletti, F; DI MARCO, Roberto; Patti, F; Reggio, E; Nicoletti, A; Zaccone, P; Stivala, F; Meroni, Pl; Reggio, A.
Sodium fusidate in Gillain-Barre syndrome: a case report
1998-01-01 Nicoletti, F; Nicoletti, A; Giuffrida, S; DI MARCO, Roberto; Meroni, P; Bendtzen, K; Lunetta, M.
Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice
1999-01-01 Xiang, M; Zaccone, P; DI MARCO, Roberto; Magro, G; DI MAURO, M; Beltrami, B; Meroni, Pl; Nicoletti, F.
Sodium fusidate in steroid resistant relapses of multiple sclerosis
1999-01-01 Nicoletti, F; Patti, F; Nicoletti, A; L'Espiscopo, Mr; DI MARCO, Roberto; Bendtzen, K; Reggio, A.
Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice
1999-01-01 Xiang, M; Zaccone, P; DI MARCO, Roberto; Harris, R; Magro, G; DI MAURO, M; Meroni, Pl; Garotta, G; Nicoletti, F.
Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease
1999-01-01 Nicoletti, F; DI MARCO, Roberto; Zaccone, P; Magro, G; DI MAURO, M; Grasso, S; Meroni, P. L.
Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement of IL-10
1999-01-01 DI MARCO, Roberto; Khademi, M; Wallstrom, E; Muhallab, S; Nicoletti, F; Olsson, T.
Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency
1999-01-01 DI MARCO, Roberto; Xiang, M; Zaccone, P; Leonardi, C; Franco, S; Meroni, P; Nicoletti, F.
Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism
2000-01-01 Nicoletti, F; DI MARCO, Roberto; Zaccone, P; Salvaggio, A; Magro, G; Bendtzen, K; Meroni, P.
Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin
2000-01-01 Nicoletti, F; DI MARCO, Roberto; Conget, I; Gomis, R; EDWARDS C., Rd; Papaccio, G; Bendtzen, K; Sandler, S.
Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis
2000-01-01 Khademi, M; Wallstrom, E; Andersson, M; Piehl, F; DI MARCO, Roberto; Olsson, T.
Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein
2000-01-01 Nicoletti, F; Zaccone, P; Xiang, M; Magro, G; DI MAURO, M; DI MARCO, Roberto; Garotta, G; Meroni, P.
The antiinflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells
2000-01-01 Nicoletti, F; DI MARCO, Roberto; Patti, F; Nicoletti, A; Leonardi, C; Reggio, E; Meroni, P; Reggio, A.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile